- Home
- LCTX vs DSAC Comparison
LCTX vs DSAC Comparison
Compare LCTX & DSAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCTX | DSAC |
|---|---|---|
| Founded | 1990 | 2025 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.7M | 345.6M |
| IPO Year | 1996 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LCTX | DSAC |
|---|---|---|
| Price | $1.12 | $10.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | ★ 891.7K | 64.5K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,556,000.00 | N/A |
| Revenue This Year | $109.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $1.00 | $9.90 |
| 52 Week High | $2.09 | $10.47 |
Technical Indicators
Market Signals| Indicator | LCTX | DSAC |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 53.96 |
| Support Level | $1.00 | $9.90 |
| Resistance Level | $1.18 | $10.18 |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 46.43 | 0.00 |
Price Performance
Historical ComparisonAbout LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
About DSAC Daedalus Special Acquisition Corp. Class A Ordinary Shares
Daedalus Special Acquisition Corp is a blank check company.